Sangamo

Views & Analysis
Card image cap

Gene editing: beyond the hype

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities.

Views & Analysis
Card image cap

Q&A: Sangamo’s Duncan McKay on genomic medicines

We talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future of genomic medicines and how healthcare systems may need to adapt to